AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01847001
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
Trial: NCT01847001
Drug: Premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
Trial: NCT01847001
Drug: Anti-nausea therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
Trial: NCT02611752
Drug: CAM2038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM2038 subcutaneous injection
Trial: NCT01810926
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
Trial: NCT01810926
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
Trial: NCT02235519
Drug: Azilsartan 40 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 40 mg of azilsartan during 12 weeks
Trial: NCT02462070
Drug: IDP-118 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT02462070
Drug: IDP-118 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT00321711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
Trial: NCT00133302
Drug: Standard CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00133302
Drug: Bi-CHOP (dose intensified CHOP)
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00324415
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
Trial: NCT00624871
Drug: Ascorbic acid (vitamin C)
RxNorm normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV, 100 mg/kg/day, every day, for 3 days
Trial: NCT00624871
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
Trial: NCT00624871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00728559
Drug: bupivacain 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trocar site injection
Trial: NCT02003365
Drug: FX006 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release formulation
Trial: NCT02003365
Drug: FX006 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release formulation
Trial: NCT02003365
Drug: TCA IR 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulation
Trial: NCT02504996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 100 ml normal saline
Trial: NCT00891462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
Trial: NCT03361956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablet orally.
Trial: NCT01319357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally for 6 weeks
Trial: NCT00451451
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00451451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00790374
Drug: BN83495 (Cohort 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg daily BN83495 for 28 days
Trial: NCT00790374
Drug: BN83495 (Cohort 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg daily BN83495 for 28 days
Trial: NCT00145704
Drug: bisphosphonate therapy (risedronate)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate therapy given to patients with growth hormone deficiency
Trial: NCT00310427
Drug: LY686017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg administered orally on a daily basis
Trial: NCT00310427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered on a daily basis
Trial: NCT04140006
Drug: BMP Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flapped surgery for insertion of dental implant with topical application of BMP gel
Trial: NCT03325647
Drug: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Trial: NCT03325647
Drug: Placebo injectable saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Trial: NCT01303328
Drug: C1
RxNorm normalized name: PC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of the experimental gel or placebo gel.
Trial: NCT00214643
Drug: clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg
Trial: NCT01874743
Drug: Rosuvastatin 20 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients must take 20mg/day of rosavastatin during 3 months
Trial: NCT03836703
Drug: Feroglobin single daily use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Trial: NCT03836703
Drug: Feroglobin twice daily dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Trial: NCT04449887
Drug: Xiangsha Liujunzi granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
Trial: NCT02161952
Drug: Matched equivalent placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03347188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Trial: NCT03657446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo infusion
Trial: NCT01114152
Drug: AZD9742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Formulation
Trial: NCT01114152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Formulation
Trial: NCT00736957
Drug: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)
RxNorm normalized name: acetaminophen / tramadol hydrochloride Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
Trial: NCT01232231
Drug: pharmacological decolonization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
Trial: NCT00935987
Drug: CYT387
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups.
Trial: NCT02231918
Drug: MIRAPEX® - low
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02231918
Drug: MIRAPEX® - medium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02231918
Drug: MIRAPEX® - high
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04045548
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Trial: NCT04045548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Trial: NCT01692158
Drug: Heparin, Low-Molecular-Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Trial: NCT00809848
Drug: AGN-210669 ophthalmic solution, 0.075%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
Trial: NCT00809848
Drug: AGN-210669 ophthalmic solution, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
Trial: NCT00809848
Drug: AGN-210669 ophthalmic solution, 0.025%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
Trial: NCT00809848
Drug: AGN-210669 vehicle ophthalmic solution
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
Trial: NCT02160990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneously twice daily for 30 days
Trial: NCT01554085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00745251
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02666430
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01688037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03035227
Drug: Anti-Arrhythmics
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
Trial: NCT01420653
Drug: Maxigesic 325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
Trial: NCT01420653
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
Trial: NCT01420653
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
Trial: NCT01420653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, three tablets four times a day, with food for 48 hours
Trial: NCT01654861
Drug: Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
Trial: NCT03004196
Drug: Probiotic Toothpaste
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
Trial: NCT03004196
Drug: Dr. Reddy's Clohex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20% Chlorhexidine Mouthwash
Trial: NCT04499976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
Trial: NCT02600351
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT01813110
Drug: 4 g prescription omega-3 concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
Trial: NCT01813110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olive oil
Trial: NCT02298985
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day (3 capsules/day) for 6 months
Trial: NCT00545337
Drug: Insuline glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03982849
Drug: silymarin 0.7% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
Trial: NCT03383471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT04512170
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single or Mulltiple doses up to 10 days
Trial: NCT00994318
Drug: Oral Iron (Ferrous sulphate)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00533923
Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT00589901
Drug: capecitabine and cyclophosphamide
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14
Trial: NCT00657449
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
Trial: NCT00657449
Drug: rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
Trial: NCT00395772
Drug: (LMW) Heparin + Vitamin K Antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
Trial: NCT02706054
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients received an IM injection of meloxicam near the nerve root (periradicular)
Trial: NCT01884623
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01816698
Drug: Taurine granule
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 package(1.6g taurine granule) once a day after meals, 12 weeks
Trial: NCT01816698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1 package once a day after meals, 12 weeks
Trial: NCT04137432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nasal sprays contains identical ingredients except for the peptide itself.
Trial: NCT01967433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02702206
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
Trial: NCT02702206
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
Trial: NCT02758366
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02938494
Drug: IDP-123 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT02938494
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream
Trial: NCT03633617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01543971
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA127 : 300mcg/kg per day for 5 days, injection
Trial: NCT02415959
Drug: Creon® (DR/GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00323583
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00323583
Drug: glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04612582
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
Trial: NCT02736994
Drug: PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic
Trial: NCT02736994
Drug: Corega Tabs Anti-bacteria®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
Trial: NCT03336983
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
Trial: NCT00122850
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00669955
Drug: Omeprazole, amoxicillin, clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
Trial: NCT00235859
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00231296
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
Trial: NCT02468557
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.